.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Covington
Colorcon
Deloitte
US Department of Justice
Federal Trade Commission
Moodys
McKinsey
Chubb

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,125,875

« Back to Dashboard

Which drugs does patent 7,125,875 protect, and when does it expire?


Patent 7,125,875 protects SPRYCEL and is included in one NDA. There have been two Paragraph IV challenges on Sprycel.

This patent has sixty-nine patent family members in thirty-eight countries.

Summary for Patent: 7,125,875

Title:Cyclic protein tyrosine kinase inhibitors
Abstract:Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Inventor(s): Das; Jagabandhu (Mercerville, NJ), Padmanabha; Ramesh (Hamden, CT), Chen; Ping (Belle Mead, NJ), Norris; Derek J. (Trenton, NJ), Doweyko; Arthur M. P. (Long Valley, NJ), Barrish; Joel C. (Richboro, PA), Wityak; John (Robbinsville, NJ), Lombardo; Louis J. (Belle Mead, NJ), Lee; Francis Y. F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/395,503
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-001Jun 28, 2006ABRXYesNo► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-001Jun 28, 2006ABRXYesNo► Subscribe► Subscribe A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-002Jun 28, 2006ABRXYesNo► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-002Jun 28, 2006ABRXYesNo► Subscribe► Subscribe A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-003Jun 28, 2006ABRXYesNo► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-003Jun 28, 2006ABRXYesNo► Subscribe► Subscribe A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-005Oct 28, 2010RXYesNo► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-005Oct 28, 2010RXYesNo► Subscribe► Subscribe A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-004May 30, 2008ABRXYesYes► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF CANCER
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-004May 30, 2008ABRXYesYes► Subscribe► Subscribe A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,125,875

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,596,746 Cyclic protein tyrosine kinase inhibitors► Subscribe
7,153,856Cyclic protein tyrosine kinase inhibitors► Subscribe
7,189,854Cyclic protein tyrosine kinase inhibitors► Subscribe
9,382,219Cyclic protein tyrosine kinase inhibitors► Subscribe
8,993,567Cyclic protein tyrosine kinase inhibitors► Subscribe
8,716,323Cyclic protein tyrosine kinase inhibitors► Subscribe
7,091,223Cyclic protein tyrosine kinase inhibitors► Subscribe
6,979,694 Cyclic protein tyrosine kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,125,875

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine87456► Subscribe
TaiwanI351404► Subscribe
Taiwan200510403► Subscribe
Turkey200102969► Subscribe
Russian Federation2365372► Subscribe
Slovenia1610780► Subscribe
Russian Federation2005132408► Subscribe
Russian Federation2312860► Subscribe
Russian Federation2005107463► Subscribe
Russian Federation2260592► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Deloitte
Mallinckrodt
Baxter
Dow
Teva
Citi
Cipla
AstraZeneca
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot